Results · Apr-Jun 2026 · filed 10 Aug 2026
Concord Drugs Q1 FY27 results
Sales grew 54% to ₹20.9 crore from ₹13.6 crore in Apr-Jun 2025.
Operating profit grew 125% to ₹2.3 crore, an operating margin of 10.9% (up 3.4 points from a year ago).
Net profit grew 846% to ₹1.1 crore from ₹0.12 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −45%, net profit +111%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 20.9 | 13.6 | +54% |
| Operating profit (EBITDA) | 2.3 | 1.0 | +125% |
| Operating margin | 10.9% | 7.5% | +3.4 pts |
| Net profit | 1.1 | 0.1 | +846% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 12 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 10 Aug 2026Financial Results For Quarter Ended 30 June 2026
- 10 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.